- AU$2.51bn
- AU$2.52bn
- $17.20m
Brief: FDA Approves First Mesenchymal Stromal Cell Therapy To Treat Steroid-Refractory Acute Graft-Versus-Host Disease
US FDA approves Mesoblast's cell therapy for graft-versus-host disease (updated)
US FDA approves Mesoblast's cell therapy for graft-versus-host disease
Brief: Mesoblast To Be Added To Nasdaq Biotechnology Index
Brief: Mesoblast Says FDA Grants Mesoblast RMAT Designation
Australia's Mesoblast jumps most in 2 months on capital raise
Brief: Mesoblast Updates On Option To Issue Up To $50M Convertible Notes
Brief: FDA Accepts Mesoblast’S Biologics License Application For Ryoncil®
Brief: Mesoblast Says US FDA Accepts BLA Resubmission For Remestemcel-L
Brief: Mesoblast Ltd Says Mesoblast Resubmits BLA With FDA For Ryoncil Approval
Brief: Mesoblast Says Joseph R. Swedish Has Chosen To Transition From Chair
Australia's Mesoblast extends gain on FDA support for proposed drug licence application
Australia's Mesoblast eyes best day in 4 years on FDA support; Jefferies raises PT
Australia's Mesoblast eyes best day in 4 years on FDA support
Mesoblast climbs on FDA support for heart failure drug approval
Australia's Mesoblast rises on FDA support for heart failure drug approval
Brief: Mesoblast Says US FDA Supports Accelerated Approval Pathway For Rexlemestrocel-L
Brief: Mesoblast Posts HY Loss Attributable $32.5 Million
Mesoblast Ltd expected to post a loss of 15 cents a share - Earnings Preview